(Total Views: 174)
Posted On: 07/12/2025 7:18:26 PM
Post# of 8485
Smart Relief Alliance
BIEL - Viant - VLMS: Connected Pain Therapy Meets Scalable Digital Health
Value Proposition
An FDA-cleared wearable pain therapy platform—ActiPatch & RecoveryRx—transformed into a smartphone-connected, AI-powered solution through Viant Medical’s device engineering and VLMS Global Healthcare’s reimbursement infrastructure. Together, we redefine chronic pain management in a market craving low-cost, data-driven, non-pharma solutions.
Market Timing
Chronic pain affects 50M+ U.S. adults
Health app industry: $3.7B+ (2024) growing at >18% CAGR
Reimbursement-ready, non-opioid solutions are VC hotspots post-COVID and amidst AI boom
Bioelectronic wearables market projected to hit $18B by 2028
Business Model:
Device Sales $50–$100/unit; bundled with app access
Subscriptions AI dashboard, physician tools, $5–$10/month
Data Licensing De-identified health analytics for research & pharma
B2B Partnerships Hospitals, telehealth platforms, wellness chains
Revenue Forecast
Year 1, Est. Users 100k, Avg Rev/User $25, Total Revenue $2.5M
Year 2, Est. Users 500k, Avg Rev/User $30, Total Revenue $15M
Year 3, Est. Users 1M, Avg Rev/User $35, Total Revenue $35M
Low CAC via retail channels & chronic pain communities. High LTV with subscription, device replacement, and AI coaching.
Strategic Team
BIEL: Proprietary PEMF tech, FDA clearances, existing retail footprint
Viant Medical: IoT device design, app firmware, HIPAA-compliant platform scaling
VLMS Global: CMS coding, reimbursement ops, backend analytics
Keith Nalepka: Sales architect; launched BIEL products across Walgreens, CVS, Target
Regulatory Advantage
ActiPatch is FDA-cleared for OTC use
VLMS actively supports CMS coding approval
HIPAA-compliant data and remote care platform ready
Competitive Edge
Only OTC pain wearables with real clinical studies
Early mover in connected PEMF therapy
Physician integration + smart analytics = precision care
BIEL - Viant - VLMS: Connected Pain Therapy Meets Scalable Digital Health
Value Proposition
An FDA-cleared wearable pain therapy platform—ActiPatch & RecoveryRx—transformed into a smartphone-connected, AI-powered solution through Viant Medical’s device engineering and VLMS Global Healthcare’s reimbursement infrastructure. Together, we redefine chronic pain management in a market craving low-cost, data-driven, non-pharma solutions.
Market Timing
Chronic pain affects 50M+ U.S. adults
Health app industry: $3.7B+ (2024) growing at >18% CAGR
Reimbursement-ready, non-opioid solutions are VC hotspots post-COVID and amidst AI boom
Bioelectronic wearables market projected to hit $18B by 2028
Business Model:
Device Sales $50–$100/unit; bundled with app access
Subscriptions AI dashboard, physician tools, $5–$10/month
Data Licensing De-identified health analytics for research & pharma
B2B Partnerships Hospitals, telehealth platforms, wellness chains
Revenue Forecast
Year 1, Est. Users 100k, Avg Rev/User $25, Total Revenue $2.5M
Year 2, Est. Users 500k, Avg Rev/User $30, Total Revenue $15M
Year 3, Est. Users 1M, Avg Rev/User $35, Total Revenue $35M
Low CAC via retail channels & chronic pain communities. High LTV with subscription, device replacement, and AI coaching.
Strategic Team
BIEL: Proprietary PEMF tech, FDA clearances, existing retail footprint
Viant Medical: IoT device design, app firmware, HIPAA-compliant platform scaling
VLMS Global: CMS coding, reimbursement ops, backend analytics
Keith Nalepka: Sales architect; launched BIEL products across Walgreens, CVS, Target
Regulatory Advantage
ActiPatch is FDA-cleared for OTC use
VLMS actively supports CMS coding approval
HIPAA-compliant data and remote care platform ready
Competitive Edge
Only OTC pain wearables with real clinical studies
Early mover in connected PEMF therapy
Physician integration + smart analytics = precision care
(1)
(0)
